ClearNote Health

Executive Summary

ClearNote Health is a private, San Diego-based diagnostics company developing liquid biopsy tests based on a proprietary epigenomics platform. Founded in 2019, the company focuses on detecting cancers with high mortality rates—such as pancreatic, ovarian, and lung cancers—at early, more treatable stages. Its technology analyzes DNA methylation patterns in cell-free DNA from a simple blood draw, offering a non-invasive alternative to traditional tissue biopsies. The platform's ability to distinguish between different cancer types and stages positions ClearNote to address significant unmet needs in cancer screening and monitoring. While the company has not yet commercialized a product, its early-stage clinical data suggest potential for high specificity and sensitivity, which could differentiate it from competitors in the liquid biopsy space. ClearNote operates in a rapidly evolving market with strong demand for early detection tools, and its progress will depend on successful clinical validation and regulatory clearance. ClearNote Health's epigenomics approach has the potential to transform cancer diagnostics by enabling earlier intervention. The company's strategy appears to focus on pan-cancer detection, initially targeting high-mortality indications where early diagnosis can dramatically improve outcomes. As a private entity with limited public data, ClearNote may be positioning for a Series C or later funding round to support pivotal trials. Success will hinge on demonstrating robust clinical performance, navigating FDA regulatory pathways, and forming strategic partnerships for commercialization. With the liquid biopsy market projected to exceed $10 billion by 2030, ClearNote Health occupies a promising niche if it can deliver on its technology's promise.

Upcoming Catalysts (preview)

• Q4 2026Initiation of a Pivotal Clinical Trial for Pancreatic Cancer Detection60% success
• Q2 2026Series B/C Funding Round to Support Clinical Development70% success
• Q3 2026Peer-Reviewed Publication of Clinical Validation Data75% success